 Håkan Björklund |
PH.D. in Neuroscience from Karolinska Institutet, Sweden. Swedish citizen.
Mr. Björklund is the former CEO of Nycomed, which was sold to Takeda Pharmaceuticals in 2011 for €9.6 billion. Under Mr. Björklund’s leadership from 1999 to 2011, Nycomed grew from a predominantly Scandinavian business into a global pharmaceutical company with leading market positions in Europe, Russia/CIS, Brazil and Latin America. Prior to Nycomed, Mr. Björklund was Regional Director at Astra (now AstraZeneca) and, earlier, President of Astra Draco. Mr. Björklund is currently Chairman of the Board of Directors at Swedish Orphan Biovitrum AB (Sobi) and Qiagen, and a Board member at Bonesupport. He was previously a member of the Board of Directors of Alere Inc, Coloplast A/S, H.Lundbeck A/S, Atos Medical AB, Danisco A/S, Acino International AG and Trimb Healthcare AB. |
 Magnus Lundberg |
Master of Science in Biology and Biochemistry from Åbo Akademi, Turku, Finland. Finnish citizen.
Mr. Lundberg is the former CEO of the Phadia group, the global leader in in-vitro allergy testing, which was sold to Thermo Fisher Scientific Inc. in 2011 for €2.5 billion. Under Mr. Lundberg’s leadership from 1999-2011, Phadia invested heavily to accelerate growth in revenues and EBITDA through a programme of targeted investment into sales force, new products and global geographic expansion. Prior to Phadia, Mr. Lundberg had extensive operating experience from a number of management positions within Pharmacia and was also formerly Vice President for Chiron Corporation. Mr Lundberg is currently the Chairman of the Board of Directors of Airsonett and Nextmune. He was previously a member of the Board of Directions of Onyx Pharmaceuticals and the Chairman of the Board of Directors of Atos Medical AB and ConvaTec Plc. |
 Runar Bjørklund |
MSc in Business from Lund University, Sweden. Norwegian citizen.
Mr. Bjørklund is the fomer CFO of Nycomed. Having spent 12 years at various accounting firms, Mr. Bjørklund joined Nycomed in Norway in 1992 and was appointed CFO of the Pharmaceutical division (Nycomed Pharma AS) in 1997. In 1999, Nycomed was acquired by the private equity firm Nordic Capital and Mr. Bjørklund was appinted CFO of the group, a position which he held until the eventual sale of the company in 2011. Mr. Bjørklund is currently Chairman of the Board of Directors at ConceptoMed AS, a Norwegian MedTech Company, and is a member of the Board of Directors of Bioservo Technologies AB and HEAR IT AS. |
 Anders Lundmark |
Master of Science in Business Administration and Economics from the Uppsala University. Swedish citizen.
Mr. Lundmark has 25 years of experience years as a CFO along with growth-related operational responsibilities. He has worked extensively under private equity regimes as well as in both listed and privately held companies. Mr. Lundmark was the CFO of Phadia from 2005-2011. Prior to that, he held CFO assignments with Iggesund Paperboard, Trelleborg Industries and Observer/Cision. Mr. Lundmark is currently the Chairman of Tellacq AB and Bioservo Technologies AB and a member of the Board of Directors of MedCap AB. |